These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7841311)

  • 41. Oxidized phospholipids in oxidized low-density lipoprotein reduce the activity of tissue factor pathway inhibitor through association with its carboxy-terminal region.
    Ohkura N; Hiraishi S; Itabe H; Hamuro T; Kamikubo Y; Takano T; Matsuda J; Horie S
    Antioxid Redox Signal; 2004 Aug; 6(4):705-12. PubMed ID: 15242551
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bacterial expression, purification, and partial characterization of amino acids 94-155 of human tissue factor pathway inhibitor (TFPI) as an inhibitor of blood coagulation factor Xa.
    Day KC; Welsch DJ
    Thromb Res; 1992 Dec; 68(4-5):369-81. PubMed ID: 1290165
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma.
    Novotny WF; Girard TJ; Miletich JP; Broze GJ
    J Biol Chem; 1989 Nov; 264(31):18832-7. PubMed ID: 2553722
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of the inhibitory effects of ApoB100 and tissue factor pathway inhibitor on tissue factor and the influence of lipoprotein oxidation.
    Ettelaie C; Wilbourn BR; Adam JM; James NJ; Bruckdorfer KR
    Arterioscler Thromb Vasc Biol; 1999 Jul; 19(7):1784-90. PubMed ID: 10397699
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tissue factor pathway inhibitor activity associated with LDL is inactivated by cell- and copper-mediated oxidation.
    Lesnik P; Dentan C; Vonica A; Moreau M; Chapman MJ
    Arterioscler Thromb Vasc Biol; 1995 Aug; 15(8):1121-30. PubMed ID: 7627705
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients.
    Lindahl AK; Jacobsen PB; Sandset PM; Abildgaard U
    Blood Coagul Fibrinolysis; 1991 Dec; 2(6):713-21. PubMed ID: 1799658
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity.
    Nordfang O; Bjørn SE; Valentin S; Nielsen LS; Wildgoose P; Beck TC; Hedner U
    Biochemistry; 1991 Oct; 30(43):10371-6. PubMed ID: 1931960
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma.
    Hansen JB; Huseby NE; Sandset PM; Svensson B; Lyngmo V; Nordøy A
    Arterioscler Thromb; 1994 Feb; 14(2):223-9. PubMed ID: 8305412
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Amino acid sequence and inhibitory activity of rhesus monkey tissue factor pathway inhibitor (TFPI): comparison with human TFPI.
    Kamei S; Kamikubo Y; Hamuro T; Fujimoto H; Ishihara M; Yonemura H; Miyamoto S; Funatsu A; Enjyoji K; Abumiya T
    J Biochem; 1994 Apr; 115(4):708-14. PubMed ID: 8089087
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterization of human tissue factor pathway inhibitor variants expressed in Saccharomyces cerevisiae.
    Petersen JG; Meyn G; Rasmussen JS; Petersen J; Bjørn SE; Jonassen I; Christiansen L; Nordfang O
    J Biol Chem; 1993 Jun; 268(18):13344-51. PubMed ID: 8514773
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tissue factor pathway inhibitor activity in human plasma. Measurement of lipoprotein-associated and free forms in hyperlipidemia.
    Kokawa T; Abumiya T; Kimura T; Harada-Shiba M; Koh H; Tsushima M; Yamamoto A; Kato H
    Arterioscler Thromb Vasc Biol; 1995 Apr; 15(4):504-10. PubMed ID: 7749862
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of a method to separate lipoprotein-bound and lipoprotein-depleted tissue factor pathway inhibitor. Measurement of free tissue factor pathway inhibitor activity.
    Bridey F; Lacombe C; Sustendal L; Moatti D; Combe F; Mammès O; de Prost D
    Blood Coagul Fibrinolysis; 1998 Oct; 9(7):637-43. PubMed ID: 9863713
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of heparin chain length on the interaction with tissue factor pathway inhibitor (TFPI).
    Xu X; Takano R; Nagai Y; Yanagida T; Kamei K; Kato H; Kamikubo Y; Nakahara Y; Kumeda K; Hara S
    Int J Biol Macromol; 2002 Jun; 30(3-4):151-60. PubMed ID: 12063117
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tissue factor pathway inhibitor inhibits endothelial cell proliferation via association with the very low density lipoprotein receptor.
    Hembrough TA; Ruiz JF; Papathanassiu AE; Green SJ; Strickland DK
    J Biol Chem; 2001 Apr; 276(15):12241-8. PubMed ID: 11278667
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Functional and immunologic methods for the measurement of human tissue factor pathway inhibitor.
    Bognacki J; Hammelburger J
    Blood Coagul Fibrinolysis; 1995 Jun; 6 Suppl 1():S65-72. PubMed ID: 7647224
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biochemical characterization of plasma-derived tissue factor pathway inhibitor: post-translational modification of free, full-length form with particular reference to the sugar chain.
    Mori Y; Hamuro T; Nakashima T; Hamamoto T; Natsuka S; Hase S; Iwanaga S
    J Thromb Haemost; 2009 Jan; 7(1):111-20. PubMed ID: 19017259
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Structural requirements of human tissue factor pathway inhibitor (TFPI) and heparin for TFPI-heparin interaction.
    Ye Z; Takano R; Hayashi K; Ta TV; Kato H; Kamikubo Y; Nakahara Y; Kumeda K; Hara S
    Thromb Res; 1998 Mar; 89(6):263-70. PubMed ID: 9669748
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Kinetics of the inhibition of human factor Xa by full-length and truncated recombinant tissue factor pathway inhibitor.
    Lindhout T; Willems G; Blezer R; Hemker HC
    Biochem J; 1994 Jan; 297 ( Pt 1)(Pt 1):131-6. PubMed ID: 8280090
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An enzyme linked immunosorption assay for tissue factor pathway inhibitor.
    Ostergaard PB; Beck TC; Orsted H; Svendsen A; Nordfang O; Sandset PM; Hansen JB
    Thromb Res; 1997 Sep; 87(5):447-59. PubMed ID: 9306619
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oxidation products of phospholipid-containing delta-9 fatty acids specifically impair the activity of tissue factor pathway inhibitor.
    Hiraishi S; Horie S; Seyama Y
    Biochem Biophys Res Commun; 2002 Nov; 298(4):468-73. PubMed ID: 12408975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.